Latest Articles
PRM Opens Florida's First Center of Excellence for Endometriosis and Pelvic Pain - Yahoo
PRM Opens Florida's First Center of Excellence for Endometriosis and Pelvic Pain Yahoo
Published: Oct. 22, 2025, 1:44 p.m.
Cyclana Bio - The Pharma Letter
Cyclana Bio The Pharma Letter
Published: Oct. 22, 2025, 8:51 a.m.
How hormonal imbalances in metabolic syndrome fuel women’s cancer risk - The South First
How hormonal imbalances in metabolic syndrome fuel women’s cancer risk The South First
Published: Oct. 22, 2025, 1:30 a.m.
Kissei Pharmaceutical Expands Linzagolix Reach with Canadian Licensing Deal - MSN
Kissei Pharmaceutical Expands Linzagolix Reach with Canadian Licensing Deal MSN
Published: Oct. 21, 2025, 5:24 p.m.
Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models - NFX
Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models NFX
Published: Oct. 21, 2025, 4:16 p.m.
Endometriosis and Blood Clots: What’s Normal and What’s Not - HealthCentral
Endometriosis and Blood Clots: What’s Normal and What’s Not HealthCentral
Published: Oct. 21, 2025, 1:50 p.m.
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer - Pharmacy Times
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer Pharmacy Times
Published: Oct. 21, 2025, 3:34 a.m.
Endometrial Ablation as a Safe Treatment for Adenomyosis-Related Abnormal Uterine Bleeding in Women with Cerebral Infarction: A Case Report - Frontiers
Endometrial Ablation as a Safe Treatment for Adenomyosis-Related Abnormal Uterine Bleeding in Women with Cerebral Infarction: A Case Report Frontiers
Published: Oct. 20, 2025, 9 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E - PharmiWeb.com
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E PharmiWeb.com
Published: Oct. 20, 2025, 3:02 p.m.
Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma - Barchart.com
Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma Barchart.com
Published: Oct. 20, 2025, 2:34 p.m.
Link copied to clipboard!